ClinicalTrials.gg
RecruitingNCT07860203Updated Oct 6, 2026

Stellate Ganglion Block and Dexmedetomidine for Postoperative Sleep in Women Undergoing Laparoscopic Gynecologic Surgery

An interventional study of DEX 0.2 μg/kg/h. and SGB in Uterine Fibroids (Leiomyoma), Adenomyosis of Uterus and Endometriosis, sponsored by Catherin Zhang. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Catherin Zhang · Not applicable, Interventional, and Treatment

How we know

Updated Oct 6, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Leiomyoma with a site in China — 20 open to participants now, 23 under way, 2 of them phase 3. Leiomyoma · China.

Planned enrollment
20th of 29
100 · median 120
Started
2026
with 4 others
No phase
15 of 40
9 open now
Primary completion
2026-12
later than 14 of 22 live
Registered
39th of 40
by date
Lead sponsor
1 of 40
Catherin Zhang

Among the 40 studies in Leiomyoma with a site in China, this one is the 20th largest by planned enrollment of the 29 interventional ones that give a count, is one of 5 that started in 2026, is one of 15 with no phase, reaches primary completion later than 14 of the 22 other live ones, and was the 39th registered.

Leiomyoma

439 studies on the registry are indexed under Leiomyoma; 74 are open to participants now.

Browse Leiomyoma studies →

Open to participants now

20 of the 40 studies in Leiomyoma with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 44 Leiomyoma studies recruiting now, 23 (52%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Leiomyoma with a site in China, or all of them as a file.
02

Study summary

Study Objectives This study aims to investigate the effects of preoperative stellate ganglion block and intraoperative intravenous dexmedetomidine on postoperative sleep disturbance in patients undergoing laparoscopic gynecologic surgery, with the goals of reducing pain and postoperative adverse reactions and identifying an effective, safe, economical, and broadly applicable intervention strategy that may facilitate emergence from anesthesia, accelerate postoperative recovery, shorten the length of hospital stay, and reduce hospitalization costs.

This trial aims to determine whether preoperative stellate ganglion block (SGB) and intraoperative intravenous dexmedetomidine (DEX) can improve postoperative sleep quality in patients undergoing laparoscopic gynecologic surgery, and whether the combination of these two interventions provides an interaction effect or additional ben

03

Conditions studied

  • Uterine Fibroids (Leiomyoma)
  • Adenomyosis of Uterus
  • Endometriosis
  • Endometrial Cancer
  • Cervical Cancer
  • Ovarian Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with (ASA) physical status I-III;
  2. Age 18-75 years;
  3. Scheduled to undergo laparoscopic gynecologic surgery (laparoscopic hysterectomy or laparoscopic surgery for uterine fibroids).

Exclusion criteria

Exclusion Criteria:

  1. Preoperative sore throat or hoarseness;
  2. History of upper respiratory tract infection within the previous 2 weeks;
  3. Anticipated difficult tracheal intubation (Mallampati class III or IV, potential facial deformity, mouth opening \<3 finger breadths, etc.);
  4. Severe preoperative cardiac, hepatic, renal, or other organ dysfunction;
  5. Allergy to the local anesthetic used in the study, infection at the puncture site, or coagulation abnormalities;
  6. Cognitive impairment, hearing impairment, language impairment, a history of psychiatric illness, or difficulty communicating or cooperating because of a psychiatric disorder.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Stellate Ganglion Block + Dexmedetomidine

    Stellate ganglion block + dexmedetomidine

    Drug: DEX 0.2 μg/kg/h. · Procedure: SGB

  • Experimental
    Stellate Ganglion Block + Placebo

    Stellate ganglion block + 0.9% sodium chloride

    Procedure: SGB · Drug: 0.9% Sodium Chloride (Placebo)

  • Experimental
    Sham Stellate Ganglion Block + Dexmedetomidine

    Sham stellate ganglion block + dexmedetomidine

    Drug: DEX 0.2 μg/kg/h. · Procedure: Sham Stellate Ganglion Block

  • Placebo comparator
    Sham Stellate Ganglion Block + Placebo

    Sham stellate ganglion block + 0.9% sodium chloride

    Drug: 0.9% Sodium Chloride (Placebo) · Procedure: Sham Stellate Ganglion Block

Interventions

  • DrugDEX 0.2 μg/kg/h.

    Drug page: DextromethorphanStudies of DextromethorphanDextromethorphan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dexmedetomidine is administered by intravenous infusion after induction of anesthesia without a loading dose, at an infusion rate of 0.2μg·kg-¹·h-¹, and continued until the end of surgery.

  • ProcedureSGB

    Stellate ganglion block (SGB) is performed 15 min after induction of anesthesia by an anesthesiologist experienced in ultrasound-guided regional anesthesia, who is aware of the patient's group assignment. The patient is placed in the supine position with the neck slightly extended and rotated to the contralateral side. Under sterile conditions, a high-frequency linear-array ultrasound transducer is used to scan the anterior neck transversely at the C6 level, sequentially identifying the common carotid artery, internal jugular vein, thyroid gland, esophagus, C6 transverse process and anterior tubercle, longus colli muscle, and surrounding vascular structures. In the SGB group, an in-plane needle approach is used under real-time ultrasound guidance. After the needle tip reaches the fascial plane anterior to the longus colli muscle and negative aspiration for blood is confirmed, 5 mL of 0.375% ropivacaine is injected slowly. Spread of the local anesthetic along the surface of the longus

  • Drug0.9% Sodium Chloride (Placebo)

    An equal volume of 0.9% sodium chloride solution is administered by intravenous infusion after induction of anesthesia as a placebo for dexmedetomidine and continued until the end of surgery.

  • ProcedureSham Stellate Ganglion Block

    Participants are placed in the same position as those receiving the stellate ganglion block, and the ultrasound probe is placed on the neck in an identical manner to simulate the procedure. No needle puncture or drug injection is performed.

06

What researchers measure

Primary outcomes

  1. St. Mary's Hospital Sleep Questionnaire Score 1 Day Before Surgery

    Subjective sleep quality is assessed using the St. Mary's Hospital Sleep Questionnaire (SMHSQ). The total score ranges from 11 to 37, with higher scores indicating poorer sleep quality.

    Time frame: 1 day before surgery(ΡRE)

  2. Total Sleep Time 1 Day Before Surgery

    Total sleep time (TST), expressed in minutes, is objectively measured using a Fitbit Charge 6 wrist-worn device.

    Time frame: 1 day before surgery(PRE)

  3. Wake After Sleep Onset 1 Day Before Surgery

    Wake after sleep onset is the total duration of wakefulness after initial sleep onset during the assessed sleep period, measured in minutes using a Fitbit Charge 6 wrist-worn device.

    Time frame: 1 day before surgery(PRE)

  4. Sleep Efficiency 1 Day Before Surgery

    Sleep efficiency is calculated as total sleep time (TST) divided by the sum of total sleep time and wake after sleep onset (WASO), multiplied by 100. TST and WASO are obtained using a Fitbit Charge 6 wrist-worn device. Values range from 0% to 100%, with higher values indicating a greater proportion of the assessed sleep period spent asleep.

    Time frame: 1 day before surgery(PRE)

  5. St. Mary's Hospital Sleep Questionnaire Score on Postoperative Day 1

    Subjective sleep quality is assessed using the St. Mary's Hospital Sleep Questionnaire (SMHSQ). The total score ranges from 11 to 37, with higher scores indicating poorer sleep quality.

    Time frame: Postoperative Day 1(POD1)

  6. Total Sleep Time on Postoperative Day 1

    Total sleep time (TST), expressed in minutes, is objectively measured using a Fitbit Charge 6 wrist-worn device.

    Time frame: Postoperative day 1

  7. Wake After Sleep Onset on Postoperative Day 1

    Wake after sleep onset is the total duration of wakefulness after initial sleep onset during the assessed sleep period, measured in minutes using a Fitbit Charge 6 wrist-worn device.

    Time frame: Postoperative day 1(ΡOD1)

  8. Sleep Efficiency on Postoperative Day 1

    Sleep efficiency is calculated as total sleep time (TST) divided by the sum of total sleep time and wake after sleep onset (WASO), multiplied by 100. TST and WASO are obtained using a Fitbit Charge 6 wrist-worn device. Values range from 0% to 100%, with higher values indicating a greater proportion of the assessed sleep period spent asleep.

    Time frame: Postoperative day 1(ΡOD1)

  9. St. Mary's Hospital Sleep Questionnaire Score on Postoperative Day 2

    Subjective sleep quality is assessed using the St. Mary's Hospital Sleep Questionnaire (SMHSQ). The total score ranges from 11 to 37, with higher scores indicating poorer sleep quality.

    Time frame: Postoperative Day 2(ΡOD2)

  10. Total Sleep Time on Postoperative Day 2

    Total sleep time (TST), expressed in minutes, is objectively measured using a Fitbit Charge 6 wrist-worn device.

    Time frame: Postoperative day 2

  11. Wake After Sleep Onset on Postoperative Day 2

    Wake after sleep onset is the total duration of wakefulness after initial sleep onset during the assessed sleep period, measured in minutes using a Fitbit Charge 6 wrist-worn device.

    Time frame: Postoperative day 2(POD2)

  12. Sleep Efficiency on Postoperative Day 2

    Sleep efficiency is calculated as total sleep time (TST) divided by the sum of total sleep time and wake after sleep onset (WASO), multiplied by 100. TST and WASO are obtained using a Fitbit Charge 6 wrist-worn device. Values range from 0% to 100%, with higher values indicating a greater proportion of the assessed sleep period spent asleep.

    Time frame: Postoperative day 2(POD2)

Secondary outcomes

  1. Postoperative Pain Intensity at 6 Hours

    Postoperative pain intensity is assessed using the Visual Analog Scale. Scores range from 0 to 10, with 0 indicating no pain and 10 indicating the worst imaginable pain. Higher scores indicate greater pain intensity.

    Time frame: 6 hours after surgery

  2. Postoperative Pain Intensity at 24 Hours

    Postoperative pain intensity is assessed using the Visual Analog Scale. Scores range from 0 to 10, with 0 indicating no pain and 10 indicating the worst imaginable pain. Higher scores indicate greater pain intensity.

    Time frame: 24 hours after surgery

  3. Postoperative Pain Intensity at 48 Hours

    Postoperative pain intensity is assessed using the Visual Analog Scale. Scores range from 0 to 10, with 0 indicating no pain and 10 indicating the worst imaginable pain. Higher scores indicate greater pain intensity.

    Time frame: 48 hours after surgery

  4. Total Intraoperative Sufentanil Consumption

    The cumulative dose of sufentanil administered to each participant from induction of anesthesia to the end of surgery is recorded in micrograms.

    Time frame: From induction of anesthesia to the end of surgery

  5. Total Intraoperative Remifentanil Consumption

    The cumulative dose of remifentanil administered to each participant from induction of anesthesia to the end of surgery is recorded in milligrams.

    Time frame: From induction of anesthesia to the end of surgery

  6. Number of Rescue Analgesia Administrations

    The total number of rescue analgesia administrations received by each participant during the first 48 hours after surgery is recorded.

    Time frame: From the end of surgery to 48 hours after surgery.

  7. Mean Arterial Pressure

    Mean arterial pressure (MAP), expressed in mmHg, is recorded at five prespecified time points to assess perioperative hemodynamic changes.

    Time frame: Before induction of anesthesia (T0), at skin incision (T1), 30 minutes after the start of surgery (T2), 60 minutes after the start of surgery (T3), and at the end of surgery (T4).

  8. Heart Rate

    Heart rate (HR), expressed in beats per minute, is recorded at five prespecified time points to assess perioperative hemodynamic changes.

    Time frame: Before induction of anesthesia (T0), at skin incision (T1), 30 minutes after the start of surgery (T2), 60 minutes after the start of surgery (T3), and at the end of surgery (T4).

  9. Number of Participants With Local Anesthetic Systemic Toxicity

    The number of participants who experience local anesthetic systemic toxicity is recorded. Each participant is counted once, regardless of the number of episodes.

    Time frame: From administration of the first study intervention to 48 hours after surgery.

  10. Number of Participants With Puncture-Site Hematoma

    The number of participants who develop a puncture-site hematoma is recorded. Each participant is counted once, regardless of the number of episodes.

    Time frame: From administration of the first study intervention to 48 hours after surgery.

  11. Number of Participants With Puncture-Site Infection

    The number of participants who develop a puncture-site infection is recorded. Each participant is counted once, regardless of the number of episodes.

    Time frame: From administration of the first study intervention to 48 hours after surgery.

  12. Number of Participants With Unintended Nerve Block

    The number of participants who experience an unintended nerve block is recorded. Each participant is counted once, regardless of the number of episodes.

    Time frame: From administration of the first study intervention to 48 hours after surgery.

  13. Number of Participants With Pneumothorax

    The number of participants who develop pneumothorax is recorded. Each participant is counted once, regardless of the number of episodes.

    Time frame: From administration of the first study intervention to 48 hours after surgery.

  14. Number of Participants With Bradycardia

    The number of participants who experience bradycardia is recorded. Each participant is counted once, regardless of the number of episodes.

    Time frame: From administration of the first study intervention to 48 hours after surgery.

  15. Number of Participants With Hypotension

    The number of participants who experience hypotension is recorded. Each participant is counted once, regardless of the number of episodes.

    Time frame: From administration of the first study intervention to 48 hours after surgery.

  16. Number of Participants With Hypoxemia

    The number of participants who experience hypoxemia is recorded. Each participant is counted once, regardless of the number of episodes.

    Time frame: From administration of the first study intervention to 48 hours after surgery.

  17. Number of Participants With Postoperative Nausea or Vomiting

    The number of participants who experience nausea, vomiting, or both during the first 48 hours after surgery is recorded. Each participant is counted once, regardless of the number of episodes or whether both symptoms occur.

    Time frame: From the end of surgery to 48 hours after surgery.

  18. Number of Participants With Postoperative Headache or Dizziness

    The number of participants who experience headache, dizziness, or both during the first 48 hours after surgery is recorded. Each participant is counted once, regardless of the number of episodes or whether both symptoms occur.

    Time frame: From the end of surgery to 48 hours after surgery.

  19. Number of Participants With Postoperative Nightmares or Excessive Dreaming

    The number of participants who report nightmares, excessive dreaming, or both during the first 48 hours after surgery is recorded. Each participant is counted once, regardless of the number of episodes or whether both symptoms occur.

    Time frame: From the end of surgery to 48 hours after surgery.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Yang RZ, Li YZ, Liang M, Yu JJ, Chen ML, Qiu JJ, Lin SZ, Wu XD, Zeng K. Stellate Ganglion Block Improves Postoperative Sleep Quality and Analgesia in Patients with Breast Cancer: A Randomized Controlled Trial. Pain Ther. 2023 Apr;12(2):491-503. doi: 10.1007/s40122-022-00473-y. Epub 2023 Jan 18. PubMed 36652140 ↗
  • Goel V, Patwardhan AM, Ibrahim M, Howe CL, Schultz DM, Shankar H. Complications associated with stellate ganglion nerve block: a systematic review. Reg Anesth Pain Med. 2019 Apr 16:rapm-2018-100127. doi: 10.1136/rapm-2018-100127. Online ahead of print. PubMed 30992414 ↗
  • Lipov EG, Joshi JR, Sanders S, Wilcox K, Lipov S, Xie H, Maganini R, Slavin K. Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study. Lancet Oncol. 2008 Jun;9(6):523-32. doi: 10.1016/S1470-2045(08)70131-1. Epub 2008 May 15. PubMed 18485819 ↗
  • Kjolhede P, Langstrom P, Nilsson P, Wodlin NB, Nilsson L. The impact of quality of sleep on recovery from fast-track abdominal hysterectomy. J Clin Sleep Med. 2012 Aug 15;8(4):395-402. doi: 10.5664/jcsm.2032. PubMed 22893770 ↗
  • Manandhar T, Sitaula S, Thapa BD, Agrawal A, Thakur A. Prevalence of Hysterectomy among Gynecological Surgeries in a Tertiary Care Hospital. JNMA J Nepal Med Assoc. 2020 Dec 31;58(232):965-970. doi: 10.31729/jnma.5315. PubMed 34506386 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2026, 2 months later.

Of 53 non-industry interventional studies with no phase under Leiomyoma, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 43. This study's planned 2 months is below that.

Counting every sponsor, half of 58 studies reached it within 31 months; a quarter within 15 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 6, 2026
StartEst.
Oct 2026
Primary completionEst.
Dec 2026
CompletionEst.
Jan 2027
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860203
Lead sponsor
Catherin Zhang
Responsible party
Catherin Zhang (Resident Physician, Department of Anesthesiology, The Second People's Hospital of Huai'an) — Sponsor-investigator
First posted
Oct 6, 2026
Start date
Oct 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Jun Wang
Contact
1961440528@qq.com
+86 19552153837

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dextromethorphan

Start the discussion